Kitov to Host Business Update Conference Call on Monday, July 2 Tel Aviv, Israel

to Host Business Update Conference Call on Monday, July 2

Aviv, Israel - June 27, 2018 -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV), an innovative biopharmaceutical company,

today announced that it will host a business update conference call on Monday July 2nd at 8:30 am Eastern Time. Management

will discuss Kitov's recent activities and accomplishments and provide information about Consensi , including efforts

to finalize US commercialization partnerships, recent positive pre-clinical data for NT219, and financial information.

July 2nd @ 8:30am Eastern Time

Available Through July 16th:

Kitov Pharmaceuticals

Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory

and clinical-trial expertise, Kitov's veteran team of healthcare and business professionals maintains a proven track record

in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, Consensi achieved the

primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the FDA for patients suffering

from osteoarthritis pain and hypertension. NT219, which is developed by its majority-owned subsidiary, TyrNovo Ltd., is a novel

patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering

development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid

ROI and long-term potential to investors, while making a meaningful impact on people's lives.

Ltd., a Kitov Pharma (NASDAQ/TASE: KTOV) company, is a developer of novel small molecules in the oncology therapeutic field. TyrNovo

is developing NT219, an oncology product designed to be used in combination with other oncology drugs. NT219 is a small molecule

dual inhibitor of Insulin Receptor Substrate (IRS1/2) and of Signal Transducer and Activator of Transcription (STAT3), two signal

pathways that are involved in the development of cancer drug resistance. In combination with various approved oncology drugs,

NT219 has demonstrated potent anti-tumor effects and increased survival in various cancer models, including sarcoma, melanoma,

pancreatic, lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is through the prevention of acquired

resistance in tumors and by regression of resistant tumors. For more information on TyrNovo please visit http://www.tyrnovopharma.com.

Statements and Kitov Pharma's Safe Harbor Statement

statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements

within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking

statements include, but are not limited to, statements concerning the amount of proceeds the Company expects to receive from the

sale of the American Depository Shares in the registered direct offering, the closing of the transaction described in this press

release, which is subject to customary conditions, and other statements that are not statements of historical fact, and may be

identified by words such as "believe", "expect", "intend", "plan", "may",

"should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations

of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You

should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking

statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a

number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other

factors that may cause our actual results, performance or achievements to be significantly different from any future results,

performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute

to such differences include, among others, risks relating to: the fact that drug development and commercialization involves a

lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical

products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical

trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty

in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of

the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment

and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market

reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products;

patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products;

our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference

or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure

to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an investigation by the Israel

Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our

securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary

in order to commercialize our products, and other factors that are discussed in our in our Annual Report on Form 20-F for the

year ended December 31, 2017 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties

under Risk Factors' in our Registration Statements and Annual Reports. These are factors that we believe could cause

our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely

affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention

or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a

result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult

any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.gov